ANAB

60.55

14.61% 7.72

Pre-mercato: 59.05 -1.50 -2.48%

Anaptysbio Inc (ANAB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$52.83

Aprire:

$56.08

Volume 24 ore:

1.10M

Relative Volume:

2.43

Capitalizzazione di mercato:

$1.68B

Reddito:

$169.47M

Utile/perdita netta:

$-84.63M

Rapporto P/E:

-21.48

EPS:

-2.8189

Flusso di cassa netto:

$-145.42M

1 W Prestazione:

+9.87%

1M Prestazione:

+25.16%

6M Prestazione:

+187.10%

1 anno Prestazione:

+297.05%

Intervallo 1D:

$54.17

$62.69

Intervallo di 1 settimana:

$52.68

$62.69

Portata 52W:

$15.12

$62.69

Anaptysbio Inc Stock (ANAB) Company Profile

Nome

Anaptysbio Inc

Settore

Healthcare (1106)

Industria

Biotechnology (621)

Telefono

858-362-6295

Indirizzo

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Dipendente

136

Cinguettio

@anaptysbio

Prossima data di guadagno

2024-11-08

Ultimi documenti SEC

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ANAB Anaptysbio Inc	60.55	1.46B	169.47M	-84.63M	-145.42M	-2.8189
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-07	Ripresa	UBS	Buy
2025-10-13	Iniziato	Barclays	Overweight
2025-06-04	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-02-04	Iniziato	Wolfe Research	Outperform
2024-12-11	Downgrade	H.C. Wainwright	Buy → Neutral
2024-12-02	Downgrade	BTIG Research	Buy → Neutral
2024-07-22	Iniziato	H.C. Wainwright	Buy
2024-07-19	Aggiornamento	JP Morgan	Neutral → Overweight
2024-04-16	Iniziato	Leerink Partners	Outperform
2024-04-11	Iniziato	Wells Fargo	Overweight
2024-03-12	Aggiornamento	Wedbush	Neutral → Outperform
2024-02-26	Iniziato	BTIG Research	Buy
2024-02-21	Iniziato	Stifel	Buy
2024-02-16	Iniziato	Piper Sandler	Overweight
2023-05-22	Aggiornamento	JP Morgan	Underweight → Neutral
2023-05-18	Iniziato	TD Cowen	Outperform
2023-01-06	Downgrade	Raymond James	Outperform → Mkt Perform
2022-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2022-09-19	Ripresa	H.C. Wainwright	Buy
2022-09-13	Downgrade	Truist	Buy → Hold
2022-09-01	Iniziato	Raymond James	Outperform
2022-03-22	Downgrade	Guggenheim	Buy → Neutral
2021-06-22	Iniziato	H.C. Wainwright	Buy
2021-05-21	Iniziato	UBS	Neutral
2021-03-16	Aggiornamento	Truist	Hold → Buy
2021-03-09	Downgrade	Wedbush	Outperform → Neutral
2021-03-08	Downgrade	JP Morgan	Overweight → Underweight
2021-02-11	Aggiornamento	JP Morgan	Underweight → Overweight
2020-10-27	Aggiornamento	Wedbush	Neutral → Outperform
2020-10-14	Aggiornamento	Guggenheim	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Underweight
2019-11-08	Downgrade	Jefferies	Buy → Hold
2019-11-08	Downgrade	SunTrust	Buy → Hold
2019-11-08	Downgrade	Wedbush	Outperform → Neutral
2019-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2019-06-21	Downgrade	Stifel	Buy → Hold
2018-12-20	Iniziato	H.C. Wainwright	Buy
2018-11-21	Iniziato	JP Morgan	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-04-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Reiterato	Stifel	Buy
2018-03-06	Reiterato	Stifel	Buy
2018-02-15	Reiterato	SunTrust	Buy
2018-01-23	Reiterato	Credit Suisse	Outperform
2017-11-15	Iniziato	SunTrust	Buy
2017-11-09	Iniziato	Jefferies	Buy
2017-10-11	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Anaptysbio Inc Borsa (ANAB) Ultime notizie

07:36 AM

Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus

07:36 AM

01:10 AM

AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada

01:10 AM

Mar 04, 2026

AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st

Mar 04, 2026

AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights

Mar 04, 2026

AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance

Mar 04, 2026

AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com

Mar 04, 2026

AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat

Mar 04, 2026

ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat

Mar 04, 2026

H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada

Mar 04, 2026

Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com

Mar 04, 2026

AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq

Mar 04, 2026

HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus

Mar 04, 2026

GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus

Mar 04, 2026

Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus

Mar 04, 2026

Mar 03, 2026

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget

Mar 03, 2026